Lengthy timelines, fragmented development activities, late decisions, and operational gaps can prevent promising therapies from progressing efficiently. Drawing on an analysis of 2020–2024 approvals, this white paper identifies common characteristics of faster programs across therapeutic areas and explores how rare disease focus, expedited regulatory pathways, novel modalities, integrated trial design, and disciplined execution can help sponsors reduce avoidable delay without compromising data integrity or patient safety.
Download the white paper to learn how earlier decisions, regulatory alignment, and operational readiness can create the conditions for faster, more predictable drug development.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
Navigate complex regulatory requirements with expert insights and bring transparency, efficiency and predictability to your regulatory affairs strategy.
Discover unrealized connections and manage your product across the entire lifecycle, from research and development, compliance to launch and commercialization.
.svg){kind=icon}
